Company profile
iRhythm Technologies, Inc.
NASDAQ: IRTC · Healthcare · Medical - Devices
#180 of 1,418 Healthcare companies by revenue70th-percentile growth
EA Score
75B+FH 66DQ 86GM 79SS 76
v0.1 · 65/100 weight · provisional
↑ growth stability, filing timeliness · ↓ balance-sheet leverage, listing tenure
Methodology →Revenue TTM
$787.9M
Rev growth YoY (TTM)
+27.4%
Net income (FY)
-$44.6M
Employees
2,400
as of 2026-08-07
Market cap
$4.2B
as of 2026-08-07
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$747.1M$747.1M2025
Net income-$44.6M-$44.6M2025
Operating income-$57.4M-$57.4M2025
Total assets$1.0B$1.0B2025
Liabilities$867.3M$867.3M2025
Equity$152.7M$152.7M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Commercial Payors52%
Centers For Medicare And Medicaid24%
Healthcare Institutions17%
Non-contracted Third-party Payors7%
By geography
Not disclosed.
The read
What is iRhythm Technologies, Inc.’s revenue?
iRhythm Technologies, Inc. booked $747.1M in FY2025 revenue, growing 26% year over year — faster than most Healthcare companies we track, at a -6.0% net margin.
Peers · Healthcare
Collegium Pharmaceutical, Inc.73BAlphatec Holdings, Inc.77B+Corcept Therapeutics Incorporated84B+Emergent BioSolutions Inc.69BRepligen Corporation82B+NeoGenomics, Inc.72BNeighbors
San Francisco →Key facts
CEOQuentin S. Blackford
SectorHealthcare
IndustryMedical - Devices
HeadquartersSan Francisco, CA
ExchangeNASDAQ: IRTC
Employees2,400
IPO date2016-10-20
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.